HEMAB THERAPEUTICS HOLDINGS INC (COAG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$45.57+1.06%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · COAG
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company plans to initiate the Phase 3 trial in the second half of 2026.
Stated in 1 of 1 supplied quarters. Management reported: “The Company plans to initiate the Phase 3 trial in the second half of 2026.” “Ninety-two percent (92%) of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig, and the mean high-intensity annualized treated bleed event rate (ATBR) was reduced by 62% over the treatment and extension period; in the low-dose weekly regimen cohort, mean ATBR was reduced by approximately 84%.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company plans to initiate the Phase 3 trial in the second half of 2026.”
The single ascending dose portion of the study was not designed to measure efficacy, and the following preliminary clinical observations are descriptive in nature.
Stated in 1 of 1 supplied quarters. Management reported: “Across the single ascending dose cohorts, 8 of 9 evaluable patients had zero treated bleeds in the 28 days following HMB-002 dosing, with a mean ATBR of 1.6, compared with a baseline mean ATBR of 20.1 prior to treatment.” “The single ascending dose portion of the study was not designed to measure efficacy, and the following preliminary clinical observations are descriptive in nature.”
“The single ascending dose portion of the study was not designed to measure efficacy, and the following preliminary clinical observations are descriptive in nature.”
HMB-003 is also being developed to address bleeding in additional high-unmet-need conditions, including hereditary hemorrhagic telangiectasia and peri-operative bleeding management.
Stated in 1 of 1 supplied quarters. Management reported: “HMB-003 is also being developed to address bleeding in additional high-unmet-need conditions, including hereditary hemorrhagic telangiectasia and peri-operative bleeding management.” “In a preclinical model, HMB-003 achieved rapid peak plasma levels within hours and sustained antifibrinolytic activity for approximately one week, supporting the potential for cycle-matched dosing in people experiencing heavy menstrual bleeding.”
“HMB-003 is also being developed to address bleeding in additional high-unmet-need conditions, including hereditary hemorrhagic telangiectasia and peri-operative bleeding management.”
The Company believes its current cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2029.
Stated in 1 of 1 supplied quarters. Management reported: “The increase primarily reflects net proceeds of $317.2 million from the Company’s initial public offering completed in May 2026, partially offset by cash used in operating activities.” “The Company believes its current cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2029.”
“The Company believes its current cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2029.”
Continue clinical trials and regulatory progress for sutacimig as a prophylactic treatment for Glanzmann thrombasthenia and Factor VII deficiency.
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.